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ABSTRACT 
Background: We aimed to estimate the minimally important difference (MID) for interpreting 
group-level change over time, both within a group and between groups, for European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 
(EORTC QLQ-C30) scores in patients with advanced breast cancer. 
 
Patients and Methods: Data were derived from two published EORTC trials. Clinical anchors, 
e.g. performance status, were selected using correlation strength and clinical plausibility of their 
association with a particular QLQ-C30 scale. Three change status groups were formed: 
deteriorated by one anchor category, improved by one anchor category and no change. Patients 
with greater anchor changes were excluded. The mean change method was used to estimate 
MIDs for within-group change and linear regression was used to estimate MIDs for between-
group differences in change over time.  For a given QLQ-C30 scale, MID estimates from 
multiple anchors were triangulated to a single value via a correlation-based weighted average. 
 
Results: MIDs varied by QLQ-C30 scale, direction (improvement versus deterioration) and 
anchor. MIDs for within-group change ranged from 5 to 14 points (improvement) and −14 to 
−4 points (deterioration), and MIDs for between-group change over time ranged from 4 to 11 
points and from −18 to −4 points. Correlation-weighted MIDs for most QLQ-C30 scales ranged 
from 4 to 10 points in absolute values. 
 
Conclusions: Our findings aid interpretation of changes in EORTC QLQ-C30 scores over time, 
both within and between groups, and for performing more accurate sample size calculations for 
clinical trials in advanced breast cancer. 
 
 
 
Keywords: Health-related quality of life (HRQOL), EORTC QLQ-C30, Minimally important 
difference (MID), Advanced Breast cancer 
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1. INTRODUCTION 
Patient reported outcomes (PROs) such as health-related quality of life (HRQOL) are 
increasingly assessed as important endpoints in cancer clinical trials (CCT). As a result, there 
is growing interest to improve the interpretation of HRQOL data in CCT [1].  It is recognised 
that interpreting HRQOL scores merely via statistical significance might be misleading since 
small differences in mean scores can be statistically significant, even when clinical relevance 
is absent. The minimally important difference (MID) approach aids interpreting differences and 
changes in HRQOL scores as clinically meaningful [2 3, 4, 5, 6, 7]. MID can be defined as the 
smallest change in a HRQOL score that is perceived as “important” by a patient or by a third 
party (e.g. a clinician), which may indicate a change in the patient's management[2].  
MIDs are commonly estimated using anchor-based and distribution-based methods [7]. Anchor-
based methods express differences or change in HRQOL scores using other familiar variables 
that have clinical relevance [3, 7, 8, 9] or to patient/physician-derived ratings of change in the 
specific domain [4, 5, 6]. Distribution-based methods use the statistical distribution of HRQOL 
scores, e.g. standard deviation (SD) criteria or standard error of measurement (SEM), and are 
considered as supportive evidence to anchor-based methods [10]. 
This study focused on interpreting the European Organisation for Research and Treatment of 
Cancer Quality of life Questionnaire core 30 (EORTC QLQ-C30) in patients with advanced 
breast cancer. Guidelines for interpreting the QLQ-C30 were initially published by King [3] and 
Osoba et al. [4]. King [3] evaluated published evidence about differences in QLQ-C30 scores 
between groups for multiple cancer sites and clinical anchors, and found that the score range 
for small, moderate and large effects differed between the scales of the QLQ-C30. Osoba et al. 
[4] provided thresholds for interpreting small (5 to 10 points), moderate (10 to 20 points) and 
large changes (> 20 points) in QLQ-C30 scores using a global rating of change, in metastatic 
breast and small-cell lung cancer patients. Based on King [3] and Osoba et al. [4], mean 
differences ≥10 points are widely regarded as clinically meaningful for the QLQ-C30 in 
randomized clinical trials [12]. However, recent guidelines revealed that MIDs can differ by 
QLQ-C30 scale, direction of change (improvement versus deterioration) and settings [5, 6], 
rendering a widely applicable rule for MIDs highly unlikely. We therefore need to gather further 
empirical evidence on patterns of MIDs across QLQ-C30 scales, and disease sites [14].  
This study examined MIDs for group-level change in HRQOL scores over time. In contrast to 
Osoba et al. [3], we used available clinical anchors in the database. Furthermore, the guidelines 
of King [4] and Cocks et al.[5, 6] were based on meta-analyses of published studies, pooling 
across cancer sites, whereas this study used individual patient data from archived trials. 
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2. METHODS 
Data description 
Data were derived from two published phase III EORTC trials. Trial 1 assessed the clinical 
benefit of a dose-intensive anthracycline-based regimen compared with standard treatment in 
women with locally advanced breast cancer and enrolled 448 patients [15]. Trial 2 compared a 
combination of doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first 
line chemotherapy in advanced (metastatic) breast cancer, and enrolled 275 patients [16]. Both 
trials assessed HRQOL using the QLQ-C30 at baseline, during treatment and on several follow-
up times points after the end of treatment. 
 
The EORTC QLQ-C30 
The EORTC QLQ-C30 comprises 30 items, 24 of which are aggregated into nine multi-item 
scales; five functioning scales: physical (PF), role (RF), cognitive (CF), emotional (EF), and 
social (SF), three symptom scales: fatigue (FA), pain (PA), and nausea/vomiting (NV) and one 
global health status (QL) scale. The remaining six single items assess symptoms: dyspnoea 
(DY), appetite loss (AP), sleep disturbance (SL), constipation (CO), diarrhoea (DI) and 
financial impact (FI). Both trials used version 2 of the QLQ-C30, with standard scoring applied 
to the scales [17]. For consistency in signs, all scales were scored such that 0 represents the worst 
possible score and 100, the best possible score. FI was omitted from the analysis because 
suitable anchors were not available. 
 
Clinical anchor  
Anchors were selected from variables that were available in the trial data sets, e.g. physician 
examinations and common terminology criteria for adverse events (CTCAE). Anchors were 
selected for each HRQOL scale based on correlation strength. Spearman’s rank, polyserial or 
polychoric correlation was used, depending on the distribution of the pair of variables.  Anchors 
with correlations of ≥|0.30| were prioritized [10] and where achievable, anchors with much 
stronger correlations were targeted. The retained anchors were further verified for clinical 
plausibility by a panel of six breast cancer / HRQOL experts to avoid spurious findings. 
Multiple anchors could be selected for each HRQOL scale [14].  
For trial 1, the retained anchors comprised: (a) WHO performance status (PS), scored between 
0 (completely active with no limitations) and 4 (bedbound) and (b) four CTCAEs (nausea, 
vomiting, fatigue and alopecia), graded between 0 (no toxicity) to 4 (life-threatening). The only 
anchor retained for trial 2 was the PS. 
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 Definition of clinical change groups 
Three clinical change status groups (CCGs) were defined: deterioration (worsened by 1 anchor 
category), stable (no change in anchor category) and improvement (improved by 1 anchor 
category). In order not to overestimate the MIDs, change scores ≥ a 2 points change in anchor 
categories were excluded from data sets used to estimate MIDs because they were considered 
to be above the ‘minimal’ expected change. 
 
Statistical analysis 
Anchor-based methods 
Change scores of HRQOL scale/anchor pairs were computed across all pairwise time points 
and combined to provide sufficient data for examining clinically important changes. For 
example, for a subject measured at time points ta, tb and tc, change scores were computed 
between ta & tb, ta & tc and tb & tc. Hence a subject can contribute multiple change scores, and 
given their change scores, subjects can contribute to multiple CCGs. Only subjects with 
HRQOL and anchor data for a given pair of time points contributed to the calculation of change 
scores. Data from the 2 trials were pooled to estimate MIDs. 
The mean change method was used to estimate MIDs for within-group change over time. MIDs 
for improvement and deterioration were computed as the mean HRQOL change scores for the 
improvement and deterioration CCGs respectively. This is relevant for interpreting change 
within a single group of patients, and it is similar to the mean HRQOL change score over time 
for a treatment group in a trial. Effect sizes (ESs) were computed within each CCG by dividing 
the mean of the HRQOL change scores (derived from all the pairwise time point differences) 
by the SD of the HRQOL change scores over all time points. Only mean changes with an ES 
of ≥ 0.2 and <0.8 were considered appropriate for inclusion as MIDs. This was based on Cohen's 
[11] recommendations that an ES of 0.2 is small, 0.5 is moderate and ≥0.8 is large. The rationale 
was that ESs <0.2 reflect changes that are clinically unimportant, and those ≥0.8 are obviously 
more than minimally important. The difference in change scores between the improvement (or 
deterioration) CCG and no change CCG was compared using analysis of variance (ANOVA). 
A linear regression was used to estimate MIDs for differences between groups in change over 
time. For a given HRQOL scale/anchor pair, the outcome variable was the HRQOL change 
score, and the covariate was a binary anchor variable, coded as ‘stable’ = 0 and 
‘improvement’ = 1 when modelling improvement (deteriorated observations were 
excluded) and ‘stable’ = 0 and ‘deterioration’ = 1 when modelling deterioration (improved 
observations were excluded). 
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Because change scores were computed across all pairwise time points, some patients 
contributed change scores to more than one CCG, and more than one change score to a 
particular CCG. We corrected for the association between multiple change scores contributed 
by same patients by specifying a suitable covariance structure using the generalized estimating 
equations (GEE) [18]. The slope parameters for the ‘improved’ and ‘deteriorated’ covariates 
correspond to the MID for improvement and deterioration respectively. This approach is similar 
to comparing the mean HRQOL change score over time in a treatment group to a control group 
in a trial, which is why these MIDs are useful for interpreting changes over time between two 
distinct groups of patients. Furthermore, we compared the two trials by adding a “trial” effect 
in a linear regression model, separately for improving and deteriorating HRQOL scores. This 
was based on the data with PS as anchor. 
Both within-group and between-group MID estimates for a given HRQOL scale, from multiple 
anchors were triangulated to a single value via a correlation-based weighted average.  
Distribution-based methods  
The SEM, 0.2 SD, 0.3 SD and 0.5 SD were applied to HRQOL scores at two time points 
common to both trials: (i) Start of treatment (t1); time point before or on the first day of 
treatment and (ii) end of treatment (t2); last day of protocol treatment. Test–retest reliability 
estimates to compute SEM for the QLQ-C30 were based on Hjermstad et al. [19]. All analyses 
were performed using the SAS software [20].  
 
3. RESULTS 
Table 1 summarises the demographic and clinical characteristics of patients at baseline. The 
median follow-up time (in months) for HRQOL was 5.3 (SD = 16.9) for trial 1 and 1.6 (SD=2.8) 
for trial 2. An overview of the flow of patients through this study is presented on Figure S.1. 
Cross-sectional correlations ranged from 0.20 to 0.62 in absolute value, with a majority of the 
correlation coefficients being above the 0.30 threshold [7] (Table 2). Correlations between the 
change scores ranged from 0.14 to 0.51. At least one suitable anchor was constructed for eight 
of the fourteen QLQ-C30 scales that were considered for this study. The distribution of patients 
and the number of change observations across the categories of suitable anchors is summarised 
in Table S.1.   
Table 3 shows the range of MIDs from the mean change method (useful for interpreting within-
group change over time) and the linear regression (useful for interpreting between-group 
differences in change over time) for each HRQOL scale, across multiple anchors. Detailed 
results are presented in Table S.2.  
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The MIDs varied according to the scale, direction of change scores (improvement versus 
deterioration) and anchor (Figure 1). Estimates were always in the expected direction according 
to the anchor, i.e. positive versus negative change scores within the improvement versus 
deterioration CCG, respectively. Statistically significant differences (ANOVA p-value <0.05) 
were observed between the HRQOL change scores for all improvement and deterioration CCGs 
versus no change CCG.  
MIDs for within-group change (based on the mean-change method) ranged from 5 to 14 points 
(improvement) and −14 to −4 points (deterioration), and MIDs for between-group change 
(based on the linear regression) ranged from 4 to 11 points and from −18 to −4 points (Table 
3). For the majority of the QLQ-C30 scales, the estimated MIDs ranged from 4 to 10 points in 
absolute values. Adding a “trial” effect to the regression models showed no statistically 
significant differences in change scores between the two trials, hence supporting the 
combination of the two trials. 
The MIDs in Table 3 are summarised to single MID values per scale in Table 4, and ranged 
from 4 to 10 points in absolute values for most HRQOL scales. Table 4 also compares the 
anchor-based estimates to the distribution-based estimates at t1. The distribution-based 
estimates at t2 for each HRQOL scale were similar to t1, mostly within a <1 point range. All 
anchor-based estimates were ≥ 0.2 SD, with most estimates being < 0.5 SD. The anchor-based 
estimates tended to be closer to both the 0.3 SD and the 1 SEM. 
 
 
 
4. DISCUSSION 
This study examined MIDs for interpreting group-level change of EORTC QLQ-C30 scores 
over time in patients with advanced breast cancer. Anchors for each HRQOL scale were 
selected based on both the correlation strength and clinical plausibility. When available, 
multiple anchors were used per HRQOL scale to provide some reassurance about the 
plausibility of the estimated MIDs. Despite the modest correlation between anchors/scales 
change scores, most MID estimates from multiple anchors were in a narrow range (often < 5 
points) and were always in the expected direction according to the anchor change category. 
In agreement with recent findings [5, 6, 7, 8, 9], our estimates varied by HRQOL scale and direction 
of change (improvement versus deterioration). Similar to Maringwa et al. [8, 9] and Musoro et al 
[7], no systematic differences were observed in the magnitude of change between deteriorating 
and improving scores. However, other studies reported that estimates for deterioration tended 
to be larger than those for improvement [6, 21].  
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We distinguished between MIDs for interpreting the degree of change within a group (obtained 
from the mean change method), and MIDs for interpreting the degree of differences between 
groups in within-group change (obtained from linear regression). Interestingly, estimates from 
both approaches were often in the same range. For many scales, the MIDs were within the range 
of 5-10 points that was suggested by Osoba et al.[4], and also observed by Cocks et al. [5,6], 
Musoro et al [7] and  Maringwa et al. [8, 9].  However, similar to Cocks et al. [5,6], we noticed that 
the thresholds for some scales were much lower. For example, MIDs of 4 points were observed 
for the CF scale. Musoro et al [7] also reported MIDs that were as low as 3 points for the CF 
scale in patients with malignant melanoma. On the other hand, similar to Musoro et al [7], we 
observed a much bigger threshold of 18 points for the AP scale. This reinforces the evidence 
that there is no single global standard for clinically meaningful change, and scale-specific MIDs 
should therefore be selected with more caution.  
Most often investigators seeking MIDs would desire simple guidelines. However as shown in 
this article, results are often varied as a consequence of there being numerous anchors, various 
distribution-based criteria and multiple HRQOL scales. Results shown in Figure 1 and Table 3 
represent this diversity as the range of MIDs vary by the various anchors. We acknowledge that 
end-users may find such a range of options confusing. So to provide a single MID value per 
scale, we further simplified by calculating a correlation-weighted average across multiple 
anchors. End-users can choose to work with either the ranges provided in Table 3 or the single 
values provided in Table 4, whichever they feel most comfortable with. Most of the anchor-
based estimates were closer to 0.3 SD and 1 SEM compared to the commonly reported 0.5 [23]. 
A limitation of this study is that suitable anchors were not always available, hence anchor-based 
MIDs could not be estimated for seven of the EORTC QLQ-C30 scales which were omitted in 
this manuscript. Furthermore, the available anchors (performance status or CTCAE grades) 
relied exclusively on clinical observations or interpretations. Since the two trials that were used 
in this study evaluated chronic delivery of cytotoxic chemotherapy, clinical anchors such as 
CTCAE nausea, CTCAE vomiting, and CTCAE fatigue were reasonable and relevant. The 
availability of a pre-treatment baseline assessment also allows detecting persistent effects such 
as alopecia. However, such anchors might not be relevant in other settings, treatments, or 
subtypes of breast cancer. The available were also not necessarily suitable in all situations. For 
example, although CTCAE fatigue met the requirements of a plausible clinical relationship with 
the QLQ-C30 fatigue scale, the resulting correlations were too low (< 0.1) to be retained. The 
low correlation can be explained by the discrete nature of the CTCAE scale where only few 
high-grade events were scored. Moreover, due to the subjective nature of ‘fatigue’ there is likely 
also misrepresentation by physicians compared to patients’ ratings as already reported by Basch 
et al [22].This might also explain the potentially inflated MID estimates for the AP scale. Also, 
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anchors that are based on patients’ perspective of change (e.g. subjective significance 
questionnaires) were not available in our study. Nonetheless, it is reassuring to notice the 
considerable overlap between our findings and those of Osoba et al.[4], which used patients' 
ratings of change as anchor. Patients’ self-assessed rating across the different QLQ-C30 scales 
and across different disease sites are rarely available from retrospective data sources and would 
need to be planned as future research to complement our findings. 
Another limitation is that our data originate from two controlled clinical trials, each with 
specific selection and treatment criteria. Although results were consistent between the trials, 
extrapolation beyond their specific setting should be made with caution. A number of articles 
are available that provide general guidelines for selecting MIDs for the QLQ-C30 scales [5, 6, 12]. 
For instance, Cocks et al. [6] published MIDs for interpreting QLQ-C30 change scores over time 
for all 15 scales using published results from multiple cancer sites. The MID values obtained 
for the eight scales considered in this study were comparable to those presented by Cocks et al. 
[6]. These increasingly robust guidelines advocate a more nuanced approach to clinical relevance 
beyond a single threshold. 
In conclusion, our findings can help clinicians and researchers to interpret the clinical relevance 
of group-level change of QLQ-C30 scores over time in patients with advanced breast cancer.  
The fact that MIDs can vary by QLQ-C30 scale and anchor suggests that we cannot rely on 
global standards for defining clinically meaningful change. Finally, our results will also inform 
more accurate sample size calculations for clinical trials in advanced breast cancer with 
endpoints that are based on EORTC QLQ-C30 scales. 
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Table 1: Baseline demographic and clinical characteristics of the patients by study (all patients 
had advanced breast cancer) 
 Study 10921 
(N=448) 
Study 10961 
(N=275) 
Total 
(N=723) 
Performance status- N (%)                                 
 0                            394 (87.9) 119 (43.3) 513 (71.0) 
 1                            54 (12.1) 133 (48.4) 187 (25.9) 
 2                            0 (0.0) 22 (8.0) 22 (3.0) 
 Unknown                            0 (0.0) 1 (0.4) 1 (0.1) 
Number of positive nodes- N (%)                                                                                                                                                                                                                                                                                  
 N0-N1                          250 (55.8)                                                                                         144 (52.4)                                                                                        394 (54.5)                                      
 N2                             176 (39.3)                                                                                            26 (9.5)                               202 (27.9)                                  
 N4+                              0 (0.0)                                                                                             51 (18.5)                              51 (7.1)                                                                    
 Nx                               9 (2.0)                                                                                             41 (14.9)                              50 (6.9)                                                         
 N3                              13 (2.9)                                                                                          13 (4.7)                                                                                         26 (3.6)                                                             
Country- N (%)                     
 France                       97 (21.7) 41 (14.9) 138 (19.1) 
 Netherlands                  41 (9.2) 42 (15.3) 83 (11.5) 
 United Kingdom               11 (2.5) 68 (24.7) 79 (10.9) 
 Poland                       78 (17.4) 0 (0.0) 78 (10.8) 
 Belgium                      48 (10.7) 29 (10.5) 77 (10.7) 
 Canada                       68 (15.2) 0 (0.0) 68 (9.4) 
 Slovenia                     22 (4.9) 26 (9.5) 48 (6.6) 
 Switzerland                  28 (6.3) 8 (2.9) 36 (5.0) 
 Russia             27 (6.0) 0 (0.0) 27 (3.7) 
 Italy                        0 (0.0) 18 (6.5) 18 (2.5) 
 Israel                       0 (0.0) 16 (5.8) 16 (2.2) 
 South Africa                 3 (0.7) 12 (4.4) 15 (2.1) 
 Portugal                     13 (2.9) 0 (0.0) 13 (1.8) 
 Czech Republic               12 (2.7) 0 (0.0) 12 (1.7) 
 Spain                        0 (0.0) 9 (3.3) 9 (1.2) 
 Austria                      0 (0.0) 6 (2.2) 6 (0.8) 
Age                                                                                                                                                                                                       
 Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                 50.07 (9.68) 52.27 (9.61) -
 Range 26.0 - 79.0 28.0 - 70.0 - 
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Table 2: Correlations over all time points of the EORTC QLQ-C30 scale scores with suitable anchors, and correlations 
between change scores of the EORTC QLQ-C30 scales and anchors. 
  Scores Change scores 
Scale Anchor 
 
N1 (N1R) Correlation N2 (N2R) Correlation 
PF Performance status 587 (2922) -0.52 548 (8508) -0.30 
 CTCAE  Fatigue 355 (2658) -0.30 343 (11102) -0.20 
 CTCAE  Vomiting 355 (2656) -0.30 343 (11077) -0.25 
RF Performance status 587 (2922) -0.54 547 (8520) -0.20 
SF Performance status 594 (2890) -0.34 545 (8390) -0.20 
 CTCAE  Fatigue 355 (2630) -0.21 340 (10984) -0.15 
 CTCAE  Vomiting 355 (2628) -0.25 340 (10959) -0.20 
CF CTCAE  Fatigue 355 (2638) -0.20 342 (11032) -0.14 
QL CTCAE  Vomiting 355 (2628) -0.39 341 (10892) -0.30 
 CTCAE  Nausea 355 (2628) -0.39 341 (10892) -0.30 
 CTCAE  Alopecia 355 (2629) -0.39 341 (10914) -0.35 
 Performance status 585 (2893) -0.32 547 (8351) -0.25 
FA Performance status 587 (2915) -0.40 546 (8476) -0.23 
 CTCAE  Nausea 355 (2644) -0.21 341 (11014) -0.15 
 CTCAE  Vomiting 355 (2644) -0.22 341 (11014) -0.16 
NV CTCAE  Nausea 355 (2654) -0.60 343 (11050) -0.51 
 CTCAE  Vomiting 355 (2654) -0.62 343 (11050) -0.48 
AP CTCAE  Nausea 355 (2621) -0.58 343 (10816) -0.44 
 CTCAE  Vomiting 355 (2621) -0.59 343 (10816) -0.48 
N1=number of patients with at least 1 matched EORTC QLQ-C30 and an anchor form.  
N1R = number of repeated anchor/ HRQOL matched forms across all subjects. 
N2=number of patients with at least 2 matched EORTC QLQ-C30 and an anchor form. At least 2 forms are needed to 
compute change scores.  
N2R = number of repeated EORTC QLQ-C30 scale/ anchor change scores across all subjects. 
N1 (N1R) and N2 (N2R) can vary by anchor and EORTC QLQ-C30 scale 
Abbreviations: AP, appetite loss; CF, cognitive functioning; FA, fatigue; NV, nausea/vomiting; PF, physical 
functioning, QL, global quality of life; RF, role functioning; SF, social functioning;  
 
 
 
 
 
 
 
 
Table 3: Range of anchor-based MID estimates from the mean change method and linear regression. 
 Mean change method
1 Linear regression
2 
Scale Improvement  Deterioration  
Improvement Deterioration 
PF 7 to 10 -11 to -10 7 to 9 -10 to -8 
RF No MID -6 
No MID -4 
SF 7 to 9 -9 to -5 6 to 7 -11 to -5 
CF 5  -4 4  -4 
QL 10 to 14 -11 to  -5 8 to 11 - 13 to -6 
FA 8 -9 to -7 8 -8 to -6 
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NV No MID -12 No MID -14 
AP No MID -14 No MID -18 
1The mean change method is useful for interpreting within-group change over time 
2The linear regression is useful for interpreting between-group differences in change over time 
All the ESs for the no change group were < 0.2 
The symptom scores were reversed to follow the functioning scales interpretation; i.e. 0 represents the worst possible score 
and 100 the best possible score; “no MID”  is used where no MID estimate is available either due to the absence of a suitable 
anchor or ES was either <0.2 or ≥0.8 
Abbreviations: AP, appetite loss; CF, cognitive functioning; FA, fatigue; NV, nausea/vomiting; PF, physical functioning, 
QL, global quality of life; RF, role functioning; SF, social functioning  
  
  
  
Table 4: Summary of anchor-based MIDs for within and between-group changes compared with distribution-based estimates. 
 
Anchor-based MID for within-
group change 
Anchor-based MID for between-
groups difference in change 
Distribution-based QOL scores at t1 
(N = 415 to 425) 
Scale Improvement Deterioration Improvement Deterioration 0.2 SD 0.3 SD 0.5 SD 1 SEM 
PF 9 -10 8 -9 4.7 7.0 11.7 7.0 
RF No MID -6 No MID -4 5.1 7.6 12.7 10.7 
SF 8 -7 7 -8 5.3 7.9 13.1 9.5 
CF 5 -4 4 -4 4.1 6.2 10.3 8.8 
QL 12 -8 10 -10 4.9 7.3 12.2 10.3 
FA 8 -8 8 -7 4.9 7.3 12.2 10.0 
NV No MID -11 No MID -14 3.4 5.1 8.5 10.3 
AP No MID -14 No MID -18 5.2 7.8 13.1 12.0 
N=number of patients 
The within-group MIDs (from the mean change method) and the between-group MIDs (from the linear regression) were 
summarised via weighted averages based on scale/anchor pair correlation. 
The symptom scores were reversed to follow the functioning scales interpretation, i.e. 0 represents the worst possible score and 
100, the best possible score; “no MID” is used where no MID estimate is available either due to the absence of a suitable anchor 
or ES was either <0.2 or ≥0.8 
Abbreviations: t1 is the  time points for the start of treatment; AP, appetite loss; CF, cognitive functioning; FA, fatigue; NV, 
nausea/vomiting; PF, physical functioning, QL, global quality of life; RF, role functioning; SF, social functioning; 
 
 
 
Figure 1: Mean change and 95% confidence interval for improvement and deterioration EORTC QLQ-C30 
scales, across multiple anchors and at different time periods. 
Estimates are available only for scales with at least 1 suitable anchor and with effect size >=0.2 and <0.8 within 
the “deteriorate” and “improve” groups respectively.    
These mean change scores are useful for interpreting within-group change over time. 
Abbreviations: AP, appetite loss; CF, cognitive functioning; FA, fatigue; NV, nausea/vomiting; PF, physical 
functioning, QL, global quality of life; RF, role functioning; SF, social functioning. Deteriorate = worsened by 
1 anchor category, no change =no change in  anchor category and improve = improved by 1 category 
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